Charles River Labs (CRL) Tops Q2 EPS by 10c; Boosts FY11 Guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $181.56 -1.86%
Revenue Growth %: -5.1%
Financial Fact:
Amortization of intangibles: 11.83M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: -5.1%
Financial Fact:
Amortization of intangibles: 11.83M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Charles River Laboratories International, Inc. (NYSE: CRL) reported Q2 EPS of $0.70, ex-items, $0.10 better than the analyst estimate of $0.60. Revenue for the quarter came in at $288.3 million versus the consensus estimate of $287.9 million.
Sees FY2011 EPS of $2.38-$2.48, versus prior guidance of $2.20-$2.40 and the consensus of $2.39.
Sees FY2011 EPS of $2.38-$2.48, versus prior guidance of $2.20-$2.40 and the consensus of $2.39.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades Charles River Labs (CRL) to Overweight, 'strong uptick in biopharma funding beginning to transition into RFPs and bookings'
- Ennis (EBF) Reports In-Line Q1 EPS
- Pfizer reaffirms 2026 guidance after CFO transition news
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
